



LJMU Research Online

King, SL, Vanicek, N and O'Brien, TD

Dynamic muscle quality of the plantar flexors is impaired in claudicant patients with peripheral arterial disease and associated with poorer walking endurance

<http://researchonline.ljmu.ac.uk/id/eprint/955/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

King, SL, Vanicek, N and O'Brien, TD (2015) Dynamic muscle quality of the plantar flexors is impaired in claudicant patients with peripheral arterial disease and associated with poorer walking endurance. Journal of Vascular Suraerv. 62 (3). pp. 689-697. ISSN 1097-6809

LJMU has developed [LJMU Research Online](#) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

1 **Dynamic muscle quality of the plantarflexors is impaired in claudicants with peripheral**
2 **arterial disease and associated with poorer walking endurance**

3 **Authors**

4 King S.L.^{1,2} Vanicek N.^{1,3} O'Brien T.D.^{2,4}

5 1. Department of Sport, Health and Exercise Science, University of Hull, UK

6 2. Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, UK

7 3. Discipline of Exercise and Sport Science, University of Sydney, Australia

8 4. School of Sport, Health and Exercise Science, Bangor University, UK

9

10 **Corresponding author:**

11 Miss Stephanie King

12 Research Institute for Sport and Exercise Science

13 Liverpool John Moores University

14 Tom Reilly Building

15 Byrom Street

16 L3 3AF

17 Email: s.l.king@ljmu.ac.uk

18 Phone: +44 7976091341

19

20 **Keywords:** Specific tension, gastrocnemius, plantarflexors, strength, exercise

21 **Acknowledgements:** We would like to thank Professor Ian Chetter and Dr Risha Lane for
22 patient recruitment and clinical guidance

1 **Abstract**

2 **Objectives:** Peripheral arterial disease and intermittent claudication (PAD-IC) negatively
3 affects physical activity and function. There is evidence for plantarflexor muscle dysfunction
4 and weakness, however, the extent to which this dysfunction can be attributed to reduced
5 muscle size and/or quality is not yet known. This study investigated whether *in vivo*
6 plantarflexor muscle quality during static and dynamic contractions are altered by PAD-IC
7 and whether such changes are associated with impaired walking endurance (according to
8 initial and absolute claudication distances). **Methods:** A total of 22 participants were
9 recruited, consisting of 10 healthy controls and 12 claudicants with occlusion of the
10 superficial femoral artery (seven unilateral and five bilateral). Muscle quality of the
11 combined gastrocnemius muscles during static contractions was calculated by normalising
12 the estimated maximal potential muscle force to the physiological cross-sectional area of both
13 lateral and medial gastrocnemius. Muscle quality during dynamic contractions of the
14 combined plantarflexor muscles was calculated as the ratio of peak voluntary concentric
15 plantarflexor power and the summed volume of lateral and medial gastrocnemius. **Results:**
16 Dynamic muscle quality was 24% lower in both the claudicating-limb and asymptomatic-
17 limb groups compared to controls ($P=.017$ and $P=.023$). The differences were most apparent
18 at the highest contraction velocity ($180^\circ/s$). Dynamic muscle quality was associated with
19 reduced walking endurance ($R=.689$, $P=.006$ and $R=.550$, $P=.042$ for initial and absolute
20 claudication distance, respectively). The claudicating-limb group demonstrated a trend
21 towards reduced static muscle quality compared to controls (22%, $P=.084$). The relative
22 contribution of the soleus muscle to plantarflexion maximum voluntary contraction was
23 significantly higher in both claudicating-limb and asymptomatic-limb groups compared to
24 controls ($P=.012$ and $P=.018$). **Conclusions:** The muscle strength of the plantarflexors in
25 those with PAD-IC appears to be impaired at high contraction velocities. This may be

1 explained by some reduction in gastrocnemii muscle quality and a greater reliance on the
2 prominently type I fibred soleus muscle. The reduced dynamic capability of the plantarflexor
3 muscles was associated with disease severity and walking ability, therefore efforts to improve
4 plantarflexor power through dynamic exercise intervention are vital to maintain functional
5 performance.

6

7

1 **Introduction**

2 Peripheral arterial disease and intermittent claudication (PAD-IC) refers to a chronic lower-
3 limb atherosclerotic disease that primarily affects the older population⁽¹⁾. The disease
4 negatively impacts on functional ability⁽²⁾, physical activity levels⁽³⁾ and quality of life⁽⁴⁾. The
5 most frequent site of claudication pain is in the plantarflexor (triceps surae) muscles⁽⁵⁾, where
6 there are clear signs of dysfunction, such as reduced ankle power generation during gait^(6,7).
7 However, the few previous studies directly investigating plantarflexor function are
8 inconsistent about whether strength is diminished in claudicants compared to healthy
9 controls⁽⁸⁻¹⁰⁾. Plantarflexor strength is a strong predictor of mortality in men with PAD-
10 IC^(11,12), so it is essential to understand the nature of any strength impairments and the
11 underlying mechanisms, so that exercise interventions may be designed accordingly.

12

13 The “strength” of a muscle group, as measured externally by hand-held or isokinetic
14 dynamometer, depends on numerous factors, including: muscle size and quality; voluntary
15 activation level; any resistance to intended effort from co-activation of the antagonist muscle;
16 and length of the moment arm about which the muscle is working⁽¹³⁾. Muscle quality during
17 isometric contractions (often known as specific tension or specific force) is defined as the
18 maximal potential muscle force (calculated using the above factors) normalised to the
19 physiological cross-sectional area⁽¹³⁾. In PAD-IC voluntary joint moments have been
20 measured previously⁽⁸⁻¹⁰⁾ but the factors that determine externally-measured strength have
21 not. Consequently, the underlying mechanisms explaining any disease-induced strength
22 losses have not been identified, and muscle quality has not yet been quantified in claudicants.
23 Thus, it remains unknown if/how any deleterious changes in muscle properties contribute to

1 reduced functional ability. Therefore, it is not apparent exactly how exercise interventions
2 should be optimally designed to improve physical function.

3

4 Muscle quality is known to reduce with ageing and disuse⁽¹⁴⁾ and increase in response to
5 resistance training⁽¹⁵⁾. It is reasonable to assume muscle quality would be altered in
6 claudicants given that the disease primarily affects the elderly⁽¹⁾ and is associated with
7 reduced physical activity⁽³⁾. Additional factors associated with PAD-IC that may further
8 affect muscle quality include intra-muscular fat infiltration⁽¹⁶⁾, which would reduce the
9 quantity of contractile material within a given muscle, and altered fibre type composition,
10 with contradicting findings of shifts towards more type II (fast-twitch)⁽¹⁷⁻¹⁹⁾ and conversely to
11 more type I fibres (slow-twitch)^(20,21). As specific tension differs between fibre types⁽²²⁾ any
12 changes at the fibre level may affect whole muscle quality, force producing potential and thus
13 functional strength. If isometric muscle quality is altered with PAD-IC then it follows that the
14 ability to utilise this force producing potential during dynamic contraction would also be
15 impaired, especially if the proportion of fast type-II fibres is reduced. Any change in muscle
16 quality might also reduce the responsiveness of muscles to exercise training, a vital
17 component of treatment for PAD-IC⁽⁵⁾. This may contribute to the inconsistent effects
18 reported following progressive resistance training in claudicants⁽²³⁾.

19

20 The purpose of the study was to determine whether PAD-IC causes changes in the strength
21 characteristics of the plantarflexors and quality of the gastrocnemii muscles. This was
22 achieved by exploring relationships between static and dynamic measures of muscle quality
23 and disease severity (as assessed through the ankle brachial pressure index; ABPI), and
24 comparing asymptomatic and symptomatic limbs of claudicants to those of healthy controls.

1 To explore the effects of muscle quality on function, correlations were performed between
2 the factors affecting muscle strength and walking endurance (quantified through initial and
3 absolute claudication distances). Our first hypothesis was that increased disease severity
4 would be associated with lower voluntary isometric plantarflexion moments and concentric
5 plantarflexion powers, and that this would be explained by smaller muscle size and reduced
6 static and dynamic muscle quality. Our second hypothesis was that walking endurance would
7 be associated with reduced maximum isometric plantarflexion moment, concentric
8 plantarflexion power, and static and dynamic muscle quality.

9

10 **Methods**

11 *Participants*

12 Ethical approval was granted by the National Health Service Research Ethics Committee
13 (REC reference: 11/YH/0335). A total of 22 participants were recruited consisting of 12
14 claudicants (seven unilateral, five bilateral) and ten healthy controls (Table I). Claudicants
15 were recruited via consultant referral from a local outpatient vascular clinic. Male and female
16 participants aged between 55-80 years who were diagnosed with Rutherford Grade 1 Chronic
17 Limb Ischemia⁽²⁴⁾ with an arterial narrowing of the superficial femoral artery were considered
18 for inclusion. Those with extensive disease were also included, however the primary stenosis
19 identified using vascular imaging was located in the superficial femoral artery for all
20 participants. Healthy controls were recruited from the local community via email and word of
21 mouth. Individuals deemed to have severe or acute cardiovascular, musculoskeletal or
22 pulmonary illness were excluded along with those with a previous lower-limb joint
23 replacement. Any individuals with a history of neurological disorders, stroke, myocardial

1 infarction or life-limiting diseases, such as cancer, were also excluded. All participants gave
2 written informed consent prior to testing

3

4 *Disease severity*

5 Disease severity was determined using the ankle brachial pressure index/ratio (ABPI).
6 Systolic blood pressure was measured in the posterior tibial and dorsalis pedis arteries of each
7 leg and the brachial pressure of both arms, separately, using a sphygmomanometer cuff and a
8 hand held Doppler instrument (Parks Medical Electronics Inc, Oregon, USA). ABPI
9 measures for both lower limbs were taken pre- and post- a standardised exercise protocol
10 performed on a motorised treadmill (5minutes at 2.5km/h at 10% incline)⁽⁵⁾. Those unable to
11 complete 5 minutes were able to stop at the point of maximum claudication pain. In
12 accordance with standard protocol, the ABPI for both legs was then calculated as the higher
13 of the two leg artery pressures normalised to the higher brachial pressure of the two arms⁽⁵⁾.
14 The post-exercise ABPI was subsequently used to categorise the limbs of the participants as
15 well as classify disease severity. Any limb with an ABPI <0.9 was classified as claudicating
16 and represents the 'claudicating-limb' group. The asymptomatic limb of the unilateral
17 claudicants was identified (ABPI \geq 0.9) and represents the 'asymptomatic-limb' group.
18 Control participants also undertook the exercise protocol to determine ABPI values,
19 confirming the absence of PAD-IC.

20

21 *Walking endurance*

22 The 6-minute walk test was modified to be performed on level ground and combined with a
23 pain rating based on the ACSM claudication pain scale⁽²⁵⁾. This method is a reliable

1 alternative to treadmill walk tests⁽²⁶⁾ and allows participants to walk for longer than 6-minutes
 2 if they are able. Patients walked continuously along a 10m walkway at a self-selected pace
 3 and informed the investigator of the level of pain and position on the pain scale every 20m.
 4 Initial claudication distance was classed as level 1 on the pain scale and signified the onset of
 5 pain. Absolute claudication distance was classed as level 4 on the pain scale, represented
 6 maximal pain and signified the end of the test.

7

8 *Experimental protocol*

9 The static muscle quality (specific tension) of the combined gastrocnemii muscles was
 10 defined as maximal potential Achilles tendon force (equation 1) normalised to the reduced
 11 gastrocnemii physiological cross-sectional area (equation 2)⁽²⁾;

$$12 \quad 1) \text{ Maximal Achilles tendon force} = \frac{(\text{Joint MVC} + \text{Antagonist moment} - \text{Soleus moment}) * 100}{(\text{Moment arm} * \text{Voluntary activation})}$$

$$13 \quad 2) \text{ Reduced gastrocnemii PCSA} = \left(\frac{GL V}{GL FL_{MVC}} \right) * \cos \cdot GL \theta_{MVC} + \left(\frac{GM V}{GM FL_{MVC}} \right) * \cos \cdot GM \theta_{MVC}$$

14 where *PCSA* is physiological cross-sectional area, *GL* is lateral gastrocnemius, *GM* is medial
 15 gastrocnemius, *V* is muscle volume, *FL* is fascicle length and θ is pennation, both quantified
 16 during maximum voluntary contraction (MVC).

17 The methods used to determine each component of these equations are detailed below.

18

19 *Measurements and calculations for maximal Achilles tendon force*

20 *Joint moment*

1 Participants were secured into the chair of an isokinetic dynamometer (Biodex System 3,
2 Biodex Medical Systems Inc, New York, USA), sat in an upright position with their hip
3 flexed (85°), knee extended (0°) and the lateral malleolus aligned with the centre of rotation
4 of the dynamometer arm during muscle contraction. To ensure isometric muscle strength of
5 the gastrocnemii muscles was measured at the optimum joint angle, MVCs were elicited at
6 10° intervals from maximum plantarflexion to maximum dorsiflexion. Verbal encouragement
7 was given throughout all trials. Three maximal isometric plantarflexion contractions were
8 performed at each joint angle and the peak gravity corrected joint moment was taken forward
9 for further analysis. For all participants, peak joint moment was achieved at maximum
10 dorsiflexion, which was consistent with healthy populations⁽²⁸⁾. All further trials to establish
11 voluntary and antagonist activation, soleus contribution, fascicle length and pennation were
12 performed in this joint position.

13

14 *Antagonist co-activation*

15 The contribution of antagonist muscle activity to the measured joint moment was estimated
16 from the surface electromyography (EMG) (Telemetry 2400T, Noraxon, Arizona, USA) of the
17 tibialis anterior, to represent the ankle dorsiflexors. Electrode placement and skin preparation
18 were according to standardised guidelines⁽²⁹⁾. The EMG of the tibialis anterior was recorded
19 at 2000Hz synchronously with joint moments during the isometric plantarflexion contractions
20 (working as an antagonist) and then combined with the EMG-moment relationship during
21 dorsiflexion contractions (working as an agonist) to estimate the antagonist co-activation
22 moment⁽²⁷⁾.

23

1 *Soleus contribution*

2 The contribution of soleus to plantarflexion moment was quantified with additional
 3 plantarflexion contractions with the knee flexed where gastrocnemii muscle does not
 4 contribute to the measured joint moment⁽²⁸⁾. Activation changes between the two positions
 5 were corrected using the EMG-moment relationship in two joint configurations using
 6 equation 3;

7 3) Soleus moment Knee 0° =
$$\frac{\text{Soleus moment Knee } 90^\circ * \text{Soleus EMG Knee } 0^\circ}{\text{Soleus EMG Knee } 90^\circ}$$

8

9 *Activation capacity*

10 The level of muscle activation achieved during voluntary contraction was calculated using the
 11 interpolated twitch technique⁽³⁰⁾. Percutaneous neuromuscular electrical stimulation (200 μs
 12 pulse duration, 400 V; Digitimer model DS7AH, Welwyn Garden City, UK) was used to
 13 evoke involuntary twitches of the plantarflexor muscles. Maximal current intensity was
 14 determined by progressively stimulating the calf with electrical twitches of increasing current
 15 steps of 50 mA until further increments in current did not increase joint torque. Once this
 16 level was established, a superimposed twitch was evoked at the point of isometric MVC and a
 17 resting twitch was applied approximately 3 s afterwards. This was repeated during three trials
 18 at peak joint angle. The percentage of voluntary activation was calculated using equation
 19 4⁽³¹⁾:

20 4) Voluntary activation =
$$\left(1 - \frac{\text{Superimposed twitch}}{\text{Resting twitch}}\right) \times 100$$

21

1 *Measurement of moment arm length*

2 Achilles tendon moment arm length was calculated using the tendon travel method⁽³²⁾ and
3 using ultrasound imaging (50-mm probe length, MyLab50 x-vision, Esaote Biomedica,
4 Genoa, Italy) to quantify linear myotendinous junction displacement.

5

6 *Measures of muscle size at rest and architecture during MVC*

7 Participants were asked to lie prone on a plinth with their ankle plantarflexed and supported
8 on the bed with the musculature relaxed. To quantify lateral and medial gastrocnemius
9 muscle volume, serial transverse ultrasound images of each muscle were overlaid to
10 reconstruct a full anatomical cross-sectional area at 25, 50 and 75 % of muscle length.
11 Muscle volume was then calculated using the anatomical cross-sectional area's and muscle
12 length by considering each muscle as two cones at either end of two truncated cones which is
13 a reliable and valid alternative to MRI imaging⁽¹⁵⁾. Lateral and medial gastrocnemius volume
14 were combined for total gastrocnemii muscle volume.

15

16 Optimum fascicle length and pennation angle during MVC were measured from synchronised
17 sagittal-plane ultrasound video-recordings of the muscle belly of lateral and medial
18 gastrocnemius , captured at 25Hz. The frame corresponding to peak tendon force was
19 extracted for each muscle during three separate MVC trials and analysed in ImageJ (version
20 1.44, NIH, USA)⁽²⁷⁾.

21

22 *Measures of dynamic muscle quality*

1 Isokinetic plantarflexion joint power was measured across the participants' full range of
2 motion at angular velocities of 60, 90, 120 and 180 °/s in the same dynamometer set up
3 described above. These velocities were selected to represent the range of joint speeds
4 experienced during gait⁽³³⁾. Five concentric contractions were performed at each velocity.
5 Peak power from each trial was recorded and the power-velocity profile constructed. The
6 volume-normalised power-velocity relationship was established by normalising power at
7 each velocity to gastrocnemii muscle volume, since the relative size of the gastrocnemii
8 muscles and the soleus remain constant with ageing⁽³⁴⁾. Dynamic muscle quality was defined
9 as peak power normalised to gastrocnemii muscle volume. Adequate rest (>1 min) was
10 provided between trials.

11

12 *Statistical analysis*

13 A linear relationship exists between advancing age and dynamic muscle quality⁽³⁵⁾ therefore a
14 Pearson's partial product-moment correlation was performed to control for the influence of
15 age and assess relationships between disease severity (as assessed by ABPI), walking
16 endurance (as assessed by initial and absolute claudication distance) and gastrocnemii
17 physiological cross-sectional area, volume and measures pertaining to static and dynamic
18 muscle quality.

19

20 A one-way ANOVA was conducted to determine if significant between differences existed
21 between the claudicating-limb and asymptomatic-limb groups and healthy controls. Data
22 were assessed for normality, using Shapiro-Wilk's test for normality, and for outliers through

1 box plot analysis. Sidak post-hoc was applied when appropriate. Mann-Whitney *U* tests were
2 performed for non-parametric measures.

3

4 For all statistical tests, significance was accepted at $P \leq .05$ and trends were accepted at $P < .10$.
5 For correlation and regression analyses, a moderate relationship was accepted as $R = .40-.59$, a
6 strong relationship was accepted as $R = .60-.79$ and a very strong relationship was accepted as
7 $R = .80-1$ ⁽³⁶⁾. Since low ABPI values indicate high disease severity a positive relationship
8 indicates a decrease in the respective parameter with worsening disease.

9

10 **Results**

11 No significant differences were found between groups in height ($P = .230$) or mass ($P = .167$)
12 (Table I). Whilst age and gender were not exactly matched between groups, the between
13 group age-difference (~5years) was not statistically significant and likely too small to have
14 influenced our results⁽³⁵⁾ and there is no reason to believe gender differences influenced our
15 measures of muscle quality⁽²⁷⁾. Between-group differences in ABPI were consistent with
16 disease presentation. One participant (unilateral claudicant) had type II diabetes that was
17 being managed by diet intervention only. Inspection of this data, in comparison to the full
18 claudicant cohort, revealed adaptations that were in keeping with those with similar ABPI
19 values and of similar ages. We do not believe that, for this individual participant, diabetes
20 was a confounding factor.

21

22

- 1 **Table I.** Participant characteristics. Data are presented as group mean (SD) unless otherwise
 2 stated. BMI – Body mass index, ABPI – Ankle brachial pressure index.

	Claudicating- limb	Asymptomatic- limb	Healthy control
#	12	7	10
% Males	75	57	40
Age (years)	65.0 (6.7)	66.1 (7.5)	61.6 (3.6)
Height (m)	1.71 (0.08)	1.69 (0.10)	1.66 (0.09)
Mass (Kg)	81.5 (18.2)	82.3 (21.1)	72.3 (10.9)
BMI (Kg/m²)	27.7 (5.1)	28.5 (4.8)	26.1 (3.7)
ABPI pre-exercise	0.81 (0.23)	1.01 (0.16)	0.99 (0.10)
ABPI post-exercise	0.55 (0.21)	0.90 (0.06)	1.00 (0.13)
Initial claudication distance (m)	105 (45)	N/A	N/A
Absolute claudication distance (m)	265 (136)	N/A	N/A
% Hypertension	50	43	10
% Hypercholesterolemia	58	71	20
% past smokers	58	57	30
% present smokers	42	43	0

3

4

1 *Correlations*

2 Increased disease severity was not associated with any change in isometric MVC joint
3 moment or static muscle quality, but was significantly correlated with reduced power at
4 120°/s and reduced power/volume at 120°/s and 180°/s, the latter being defined as
5 significantly reduced dynamic muscle quality (all R and p values are presented in Tables II,
6 and III). A trend was observed for smaller gastrocnemii physiological cross-sectional area
7 with higher disease severity (P=.073) (Table II).

8

9 Shorter initial and absolute claudication distance were associated with larger gastrocnemii
10 muscle volume, lower activation capacity and reduced dynamic muscle quality. Shorter
11 absolute claudication distance was also correlated with reduced static muscle quality and
12 shorter moment arm lengths (all R and p values are presented in Tables II and III). Trends
13 towards an association existed between shorter absolute claudication distance and reduced
14 tendon force (P=.053) (Table II).

15

16

- 1 **Table II.** Pearson correlations (controlled for the influence of age) between disease severity (ABPI), walking endurance (ICD and ACD) and
 2 gastrocnemii size and measures of static muscle quality. PCSA – physiological cross-sectional area. Dark shaded values represent those reaching
 3 significance ($P \leq .05$) and light shaded values represent those demonstrating trends towards significance ($P < .10$).

		MVC	Soleus contribution	Activation capacity	Moment arm	Tendon force
ABPI	Correlation	.055	-.048	-.312	-.377	.198
	Significance	.847	.865	.258	.165	.480
ICD	Correlation	-.161	-.419	.589	-.424	.091
	Significance	.566	.120	.021	.116	.747
ACD	Correlation	.188	-.277	.514	-.668	.508
	Significance	.502	.318	.050	.007	.053
		Gastrocnemii volume	Gastrocnemii reduced PCSA	Static muscle quality		
ABPI	Correlation	-.368	.475	-.009		
	Significance	.117	.073	.976		
ICD	Correlation	-.858	-.386	.353		
	Significance	.000	.156	.257		
ACD	Correlation	-.851	-.079	.632		
	Significance	.029	.779	.011		

4

5

- 1 **Table III.** Pearson correlations (controlled for the influence of age) between disease severity (ABPI), walking endurance (ICD and ACD) and
 2 measures of dynamic muscle quality. Dark shaded values represent those reaching significance ($P \leq .05$).

Power		60°/s	90°/s	120°/s	180°/s
ABPI	Correlation	.071	.375	.674	.375
	Significance	.803	.398	.012	.168
ICD	Correlation	-.256	-.277	-.123	-.368
	Significance	.357	.318	.688	.177
ACD	Correlation	-.007	-.148	.064	-.262
	Significance	.981	.598	.836	.346
Power/Volume		60°/s	90°/s	120°/s	180°/s
ABPI	Correlation	.174	.323	.716	.541
	Significance	.600	.240	.006	.037
ICD	Correlation	.418	.364	.408	.689
	Significance	.121	.182	.166	.006
ACD	Correlation	.421	.263	.372	.550
	Significance	.118	.344	.211	.042

1 *Between group comparisons*

2 There were no differences between groups in isometric joint MVC, however the soleus
3 contribution to this joint moment was significantly greater in both the claudicating-limb and
4 asymptomatic-limb groups than in healthy controls ($P=.008$ and $P=.012$, respectively). The
5 claudicating-limb group demonstrated trends towards reduced static muscle quality compared
6 to healthy controls ($P=.084$) (Table IV).

7

8 At $120^\circ/\text{s}$ the asymptomatic-limb group demonstrated trends towards reduced power ($P=.071$)
9 with similar trends observed at $180^\circ/\text{s}$ in the claudicating-limb group compared to healthy
10 controls ($P=.100$). When normalised to gastrocnemii muscle volume, the asymptomatic-limb
11 group had significantly reduced power/volume at $120^\circ/\text{s}$ ($P=.036$) compared to healthy
12 controls and both the asymptomatic-limb ($P=.023$) and claudicating-limb ($P=.017$) groups
13 had significantly reduced power/volume at $180^\circ/\text{s}$ (dynamic muscle quality) (Figure 1).

14

15

1 **Table IV.** Group mean (SD) measures of static muscle quality. Dark shaded values represent
 2 those reaching significance ($P \leq .05$) and light shaded values represent those demonstrating
 3 trends towards significance ($P < .10$). PCSA – physiological cross-sectional area.

	Claudicating- limb	Asymptomatic- limb	Healthy control
MVC (Nm)	120.6 (32.5)	121.7 (36.1)	127.5 (34.3)
Antagonist co-activation (%)	2.74 (2.2)	2.35 (2.5)	2.01 (1.85)
Plantarflexor moment (Nm)	123.4 (31.8)	124.0 (35.4)	130.0 (36.9)
Soleus contribution (%)	62.7 (6.3) ^{Co}	62.1 (1.4) ^{Co}	55.6 (7.9)
Gastronemii moment (Nm)	45.1 (10.3)	46.9 (13.3)	58.1 (20.2)
Activation capacity (%)	90.7 (6.5)	87.9 (7.8)	90.4 (4.6)
Gastrocnemii moment at 100% (Nm)	49.6 (10.7)	53.5 (15.5)	64.7 (24.4)
Moment arm (cm)	3.44 (0.58)	3.71 (0.76)	3.24 (0.58)
Tendon force (N)	1500.2 (471.8)	1506.9 (431.2)	2001.7 (722.7)
<i>Muscle size and static quality</i>			
Gastrocnemii volume (cm ³)	267.4 (71.5)	249.8 (51.1)	243.1 (71.3)
Gastrocnemii reduced PCSA (cm ²)	55.4 (9.8)	54.0 (14.1)	58.1 (12.0)
Static muscle quality (N/cm ²)	27.1 (6.6) ^{Co}	28.8 (8.3)	34.5 (10.4)

4 Cl = vs Claudicating-limb group, A = vs Asymptomatic-limb group Co = vs Healthy control
 5 group

6

1




Figure 1. Group mean power-velocity (a) and normalised power-velocity (b) profiles for claudicating-limb (▲), asymptomatic-limb (△) and healthy controls (□). Dark shaded values represent those reaching significance ($P \leq 0.05$) and light shaded values represent those demonstrating trends towards significance ($P < 0.10$). Cl = vs Claudicating-limb group, A = vs Asymptomatic-limb group Co = vs Healthy control group.

1 Discussion

2 The aim of the study was to investigate the effects of peripheral arterial disease and
3 intermittent claudication (PAD-IC) on the strength, power, size and *in vivo* whole muscle
4 quality of the plantarflexors. We found no effects of disease on external measures of
5 “strength” during static or low speed contractions, but the claudicants relied on the
6 predominantly type I-fibred soleus to develop overall strength more than healthy controls.
7 Significant strength differences between claudicants and controls were apparent during higher
8 speed ($\geq 120^\circ/\text{s}$) contractions. These data support our hypotheses that the dynamic muscle
9 quality of claudicants was reduced compared to healthy controls, and this was associated with
10 poorer walking endurance. These novel findings suggest that impaired muscle quality and a
11 greater reliance on the soleus muscle contribute to reduced dynamic strength of claudicants at
12 high speeds, which in turn contributes to the impaired functional ability seen in this
13 population.

14

15 Previous studies investigating plantarflexor strength in individuals with PAD-IC are
16 inconsistent⁽⁸⁻¹⁰⁾ and comparisons between studies are confounded by differing methods of
17 strength assessment. This study quantified plantarflexor strength across a range of contraction
18 speeds, and observed no between-group differences at low velocities. However, the power
19 generating capacity of the claudicants was 13-26% lower than controls at speeds of 120-
20 $180^\circ/\text{s}$. Interestingly, this was the case for both claudicating-limb and asymptomatic-limb
21 groups. This indicates either the presence of systemic effects of ischemia in the
22 ‘asymptomatic’-limb or that deleterious adaptations were driven by the relative inactivity
23 caused by the symptomatic limb. Isometric plantarflexor strength has previously been
24 reported as a strong predictor of mortality in men with PAD-IC^(11,12); however the current

1 data suggest that dynamic contractions at higher velocities may be more sensitive to
2 functional deteriorations, which was not apparent in previous sub-group analyses⁽³⁷⁾. Future
3 functional assessments and measures of plantarflexor strength should consider the use of
4 dynamic, concentric tests in order to detect strength losses early in diagnosis and to identify
5 those with greater strength impairments.

6

7 Whilst voluntary joint moments and powers are simple and time-efficient measures, they do
8 not provide information regarding the underlying mechanisms contributing to the externally
9 measured strength. Despite minimal between-group differences in isometric MVC, a
10 substantially lower (25%, but non-significant) tendon force was found in both claudicating-
11 limb and asymptomatic-limb groups compared to controls. Combined with similar
12 physiological cross-sectional areas, this led to a trend towards reduced static muscle quality
13 (21%) in the claudicating-limb group, and a non-significant reduction of 16% in the
14 asymptomatic-limb group, compared to controls. These effects were not mirrored in the
15 correlations with ABPI, suggesting other stimuli must exist, such as physical activity levels, to
16 drive these reductions in static gastrocnemii muscle quality of claudicants.

17

18 The reduced tendon force in the claudicating-limb group, despite similar joint moments
19 between groups, can be attributed to a greater (12%) contribution of the soleus to the overall
20 joint moment, compared to healthy controls. This increased reliance on the soleus during
21 plantarflexion contractions may be linked to the proposed shift in fibre type in claudicants⁽¹⁷⁻
22 ²¹⁾. Therefore, the increased contribution from the slower, type I-dominant soleus muscle⁽³⁸⁾
23 may act as a means to reduce the metabolic cost of the task. However, during dynamic

1 contractions, a greater contribution from soleus would have a detrimental effect on the ability
2 to generate power, particularly at high speeds, which is consistent with the present data.

3

4 When muscle power was normalised to volume (dynamic muscle quality) between-group
5 differences became larger and significant associations with walking endurance and disease
6 severity were apparent. This corroborates previous reports of reduced ankle plantarflexor
7 power per kg body mass in gait^(6,7) and demonstrates the importance of plantarflexor power
8 for functional performance. The reductions in dynamic muscle quality were associated with
9 changes in walking performance that have previously been reported as clinically meaningful
10 (>50m)⁽³⁹⁾. Long-term efforts to monitor the implications of this appear warranted, and
11 quantification of dynamic muscle quality may provide a useful outcome measure in these
12 efforts. Exercise prescription is a primary treatment option in PAD-IC to improve mobility
13 and to combat muscle weakness⁽⁵⁾. It appears that such training interventions should target
14 improvements in plantarflexor power by redressing the relative contribution from the soleus
15 and gastrocnemii muscles through dynamic exercise programmes (high-velocity resistance
16 training). Future work should endeavour to assess how these important musculoskeletal
17 parameters respond to (exercise-based) interventions and whether they lead to the predicted
18 improvements in walking capacity.

19

20 Correlation analysis revealed that variations in activation capacity amongst the claudicating-
21 limb group significantly affected walking endurance. This would increase the perceived effort
22 of walking, possibly leading to altered gait mechanics to redistribute joint kinetics, and
23 consequently alter movement efficiency and endurance. Activation level was not quantified
24 during the isokinetic trials because muscle stimulation during dynamic contractions is

1 technically very challenging, particularly for the plantarflexors where the muscle group
2 works almost exclusively on the ascending limb of the force-length relationship, so
3 stimulation at optimal muscle length is not possible. Future work should endeavour to
4 investigate the activation capacity of the plantarflexor muscles during dynamic contractions,
5 since it may be different to that in isometric conditions and could contribute to the specific
6 power deficits at high velocities. This would provide greater understanding of the
7 neuromuscular adaptations caused by PAD-IC and their influence on functional performance.

8
9 Some limitations to the present study must be acknowledged. It is recognised that the present
10 sample is small with a wide range of disease severity. Nonetheless we were able to detect
11 between-group differences and meaningful associations with walking endurance, as such we
12 consider this sample adequate to confirm the hypotheses. Static muscle quality should be
13 calculated with measures of truly optimal muscle force and length, i.e., plateau of the force-
14 length relationship. As is typical for the plantarflexors, this plateau was not observed⁽²⁸⁾ and
15 we do not know whether participants reached optimal fascicle length. However, previous
16 work has shown that small changes in joint position do not significantly affect estimates of
17 muscle quality⁽²⁷⁾. By calculating the quality of the entire gastrocnemii muscle group, errors
18 associated with distributing tendon force between the lateral and medial gastrocnemii
19 muscles were avoided. However, it was necessary to assume that once soleus contribution
20 was removed, the Achilles' tendon force reflected only that produced by the gastrocnemii
21 muscle. Dynamic muscle quality was calculated as plantarflexor joint power normalised to
22 gastrocnemii muscle volume only, assuming the relative size of these muscles remains
23 constant, as is the case in ageing⁽³⁴⁾. Claudicants relied on the soleus more than healthy
24 controls did, meaning any error associated with this assumption will most likely
25 underestimate the true between-group difference in dynamic muscle quality. Additionally,

1 moment arm length was determined during passive joint rotations at rest⁽³²⁾ and it is known to
2 change during contraction⁽⁴⁰⁾. However, there is no reason to assume the change from rest to
3 contraction would be different between controls and claudicants; consequently, we consider
4 the comparisons presented in this study to remain valid.

5

6 **Conclusions**

7 The present study quantified the intrinsic quality of *in vivo* claudicant muscle for the first
8 time. Dynamic plantarflexion strength, particularly at the highest velocity, was lower in
9 claudicants compared to healthy controls and was significantly associated with disease
10 severity and impaired walking endurance. When dynamic strength was normalised to muscle
11 size (to calculate muscle quality) between group differences were larger and relationships
12 with walking endurance were stronger. The impaired function at high velocities may be
13 related to a reduction in maximal (static) muscle quality and an increased reliance on the
14 predominantly type-I fibred soleus muscle. Efforts to monitor strength at high velocities
15 appear the most appropriate way to detect functional losses early, and improving the dynamic
16 capabilities of the plantarflexors is likely to help maintain walking endurance in claudicants.

1 **References**

- 2 1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart
3 disease and stroke statistics--2011 update: a report from the American Heart Association.
4 *Circulation*. 2011;123(4):e18-e209.
- 5 2. McDermott MM, Greenland P, Liu K, Guralnik J, Criqui MH, Dolan NC, et al. Leg
6 Symptoms in peripheral arterial disease. Associated clinical characteristics and functional
7 impairment. *JAMA*. 2001;286(13):1599-606.
- 8 3. Garg PK, Tian L, Criqui MH, Liu K, Ferrucci L, Guralnik JM, et al. Physical activity
9 during daily life and mortality in patients with peripheral arterial disease. *Circulation*.
10 2006;114(3):242-8.
- 11 4. Spronk S, White JV, Bosch JL, Hunink MG. Impact of claudication and its treatment
12 on quality of life. *Semin Vasc Surg*. 2007;20(1):3-9.
- 13 5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-
14 Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Eur J Vasc*
15 *Endovasc Surg*. 2007;33 Suppl 1:S1-75.
- 16 6. Wurdeman SR, Koutakis P, Myers SA, Johanning JM, Pipinos II, Stergiou N. Patients
17 with peripheral arterial disease exhibit reduced joint powers compared to velocity-matched
18 controls. *Gait & Posture*. 2012;36(3):506-9.
- 19 7. Koutakis P, Johanning JM, Haynatzki GR, Myers SA, Stergiou N, Longo GM, et al.
20 Abnormal joint powers before and after the onset of claudication symptoms. *J Vasc Surg*.
21 2010;52(2):340-7.

- 1 8. Scott-Okafor HR, Silver KKC, Parker J, Almy-Albert T, Gardner AW. Lower
2 Extremity Strength Deficits in Peripheral Arterial Occlusive Disease Patients with
3 Intermittent Claudication. *Angiology*. 2001;52(1):7-14.
- 4 9. Camara LC, Ritti-Dias RM, Meneses AL, D'Andrea Greve JM, Filho WJ, Santarem
5 JM, et al. Isokinetic strength and endurance in proximal and distal muscles in patients with
6 peripheral artery disease. *Ann Vasc Surg*. 2012;26(8):1114-9.
- 7 10. McDermott MM, Tian L, Ferrucci L, Liu K, Guralnik JM, Liao Y, et al. Associations
8 between lower extremity ischemia, upper and lower extremity strength, and functional
9 impairment with peripheral arterial disease. *J Am Geriatr Soc*. 2008;56(4):724-9.
- 10 11. McDermott MM, Liu K, Tian L, Guralnik JM, Criqui MH, Liao Y, et al. Calf Muscle
11 Characteristics, Strength Measures, and Mortality in Peripheral Arterial Disease: A
12 Longitudinal Study. *Journal of the American College of Cardiology*. 2012;59(13):1159-67.
- 13 12. Singh N, Liu K, Tian L, Criqui MH, Guralnik JM, Ferrucci L, et al. Leg strength
14 predicts mortality in men but not in women with peripheral arterial disease. *J Vasc Surg*.
15 2010;52(3):624-31.
- 16 13. Maganaris CN, Baltzopoulos V, Ball D, Sargeant AJ. In vivo specific tension of
17 human skeletal muscle. *J Appl Physiol*. 2001;90:865-72.
- 18 14. Suetta C, Hvid LG, Justesen L, Christensen U, Neergaard K, Simonsen L, et al.
19 Effects of aging on human skeletal muscle after immobilization and retraining. *J Appl*
20 *Physiol*. 2009;107(4):1172-80.
- 21 15. Reeves ND, Narici MV, Maganaris CN. Effect of resistance training on skeletal
22 muscle-specific force in elderly humans. *J Appl Physiol*. 2004;96(3):885-92.

- 1 16. Raval Z, Liu K, Tian L, Ferrucci L, Guralnik JM, Liao Y, et al. Higher body mass
2 index is associated with more adverse changes in calf muscle characteristics in peripheral
3 arterial disease. *J Vasc Surg.* 2012;55(4):1015-24.
- 4 17. McGuigan MRM, FBronks R, Newton RU, Sharman MJ, Graham JC, Cody DV, et al.
5 Muscle fiber characteristics in patients with peripheral arterial disease. *Medical Science in*
6 *Sports Exercise.* 2001;33(12):2016-21.
- 7 18. Askew CD, Green S, Walker PJ, Kerr GK, Green AA, Williams AD, et al. Skeletal
8 muscle phenotype is associated with exercise tolerance in patients with peripheral arterial
9 disease. *J Vasc Surg.* 2005;41(5):802-7.
- 10 19. Gasparini M, Sabovic M, Gregoric ID, Simunic B, Pisot R. Increased Fatigability of
11 the Gastrocnemius Medialis Muscle in Individuals with Intermittent Claudication. *Eur J Vasc*
12 *Endovasc Surg.* 2012;44(2):170-6.
- 13 20. Regensteiner JG, Wolfel EE, Carry MR, Ringel SP, Hargarten ME, Stamm ER, et al.
14 Chronic Changes in Skeletal Muscle Histology and Function in Peripheral Arterial Disease.
15 *Circulation.* 1993;87:413-21.
- 16 21. Steinacker JM, Opitz-Gress A, Baur S, Lormes W, Bolkart K, Sunder-Plassmann L, et
17 al. Expression of myosin heavy chain isoforms in skeletal muscle of patients with peripheral
18 arterial occlusive disease. *J Vasc Surg.* 2000;31:443-9.
- 19 22. Widrick JJ, Trappe SW, Blaser CA, Costill DL, Fitts RH. Isometric force and
20 maximal shortening velocity of single muscle fibers from elite master runners. *Am J Physiol.*
21 1996;271(2 Pt 1):C666-75.

- 1 23. Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized
2 controlled trials: Walking versus alternative exercise prescription as treatment for intermittent
3 claudication. *Atherosclerosis*. 2011;218(1):1-12.
- 4 24. Rutherford RB, Baker D, Ernst C, Johnston KW, Porter JM, Ahn S, Jones, DN.
5 Recommended standards for reports dealing with lower extremity ischemia: Revised version.
6 *J Vasc Surg*. 1997;26:517-38.
- 7 25. Durstine JL, Moore GE. *ACSM's Exercise Management in Persons with Chronic*
8 *Diseases and Disabilities*. Leeds: Human Kinetics; 2003.
- 9 26. Zwierska I, Nawaz S, Walker RD, Wood RF, Pockley AG, Saxton JM. Treadmill
10 versus shuttle walk tests of walking ability in intermittent claudication. *Med Sci Sports*
11 *Exerc*. 2004;36(11):1835-40
- 12 27. O'Brien TD, Reeves ND, Baltzopoulos V, Jones DA, Maganaris CN. In vivo
13 measurements of muscle specific tension in adults and children. *Exp Physiol*.
14 2010;95(1):202-10.
- 15 28. Maganaris CN. Force-length characteristics of the in vivo human gastrocnemius
16 muscle. *Clin Anat*. 2003;16(3):215-23.
- 17 29. Hermens HJ, Freriks B, Disselhorst-Klug C, Rau G. Development of
18 recommendations for SEMG sensors and sensor placement procedures. *Journal of*
19 *Electromyography and Kinesiology*. 2000;10(5):361-74.
- 20 30. Rutherford OM, Jones DA, Newham DJ. Clinical and experimental application of the
21 percutaneous twitch superimposition technique for the study of human muscle activation. *J*
22 *Neurol Neurosurg Psychiatry*. 1986;49(11):1288-91.

- 1 31. Behm D, Power K, Drinkwater E. Comparison of interpolation and central activation
2 ratios as measures of muscle inactivation. *Muscle Nerve*. 2001;24:925-34.
- 3 32. Fath F, Blazevich AJ, Waugh CM, Miller SC, Korff T. Direct comparison of in vivo
4 Achilles tendon moment arms obtained from ultrasound and MR scans. *J Appl Physiol*.
5 2010;109(6):1644-52.
- 6 33. Mills PM, Barrett RS. Swing phase mechanics of healthy young and elderly men.
7 *Human Movement Science*. 2001;20(4–5):427-46.
- 8 34. Morse CI, Thom JM, Birch KM, Narici MV. Changes in triceps surae muscle
9 architecture with sarcopenia. *Scandinavian Physiological Society*. 2005;183:291-8.
- 10 35. McNeil CJ, Vandervoort AA, Rice CL. Peripheral impairments cause a progressive
11 age-related loss of strength and velocity-dependent power in the dorsiflexors. *J Appl Physiol*.
12 2007;102(5):1962-8.
- 13 36. Taylor R. Interpretation of the Correlation Coefficient: A Basic Review. *Journal of*
14 *Diagnostic and Medical Sonography*. 1990;6(1):35-9.
- 15 37. King S, O'Brien TD, Vanicek N. Isometric and isokinetic strength profiles of
16 claudicants with peripheral arterial disease. *Gait Posture*.2014; 39:S29-S30
- 17 38. Dahmane R, Djordjevič S, Šimunič B, Valenčič V. Spatial fiber type distribution in
18 normal human muscle: Histochemical and tensiomyographical evaluation. *J Biomech*.
19 2005;38(12):2451-9.39. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful
20 Change and Responsiveness in Common Physical Performance Measures in Older Adults. *J*
21 *Am Geriatr Soc*. 2006;54(5):743-9.

- 1 40. Fath F, Blazevich AJ, Waugh CM, Miller SC, Korff T. Interactive effects of joint
- 2 angle, contraction state and method on estimates of achilles tendon moment arms. *J Appl*
- 3 *Biomech.* 2013;29(2):241-4.